News

Activation Capital Announces Plans for Development of Innovation Center – A New Life Sciences Center at Bio+Tech Park

Activation Capital, an innovation ecosystem development organization, announced plans to develop the 102,000-square foot Innovation Center in the Bio+Tech Park in Richmond, Virginia.

The 34-acre Bio+Tech Park is a commercial life sciences hub in downtown Richmond adjacent to the VCU Medical Center at Virginia Commonwealth University, and is home to over 70 companies, research institutes, and state/federal laboratories. Activation Capital recently announced Virginia Gov. Glenn Youngkin awarded Activation Capital a $15 million portion of a total $66.7 million in grant funding for life sciences projects in the Commonwealth of Virginia.

Amy J. Broderick and Kate Hosko of Cushman & Wakefield | Thalhimer, along with David Thomann of Cushman & Wakefield’s Life Science Group in Boston, MA, have been awarded the exclusive leasing representation for the Innovation Center. Planned for delivery in late 2025, the center will feature approximately 35,000+ square feet of trophy class lab and creative office space for a lead tenant. Approximately 45,000 sf will be dedicated to an incubator operated by Activation Capital and will include shared labs, private offices, and community gathering spaces.  The new building will be located at the corner of 8th Street and Jackson Street.

“As part of our strategic plan to create a thriving ecosystem, Activation Capital will build an Innovation Center that anchors downtown Richmond’s innovation hub and serves as a magnet for innovators to build and grow deep tech companies. Once complete, the Innovation Center will catalyze downtown redevelopment around wealth-creating jobs, boost entrepreneurial growth, strengthen the region’s end-to-end pharmaceutical manufacturing cluster, and act as a platform for upskilling community members with STEM programming.,” said Chandra Briggman, President and CEO of Activation Capital

“In addition to their strong commercial real estate brokerage experience and national life science expertise, Cushman & Wakefield | Thalhimer was selected due to their alignment with Activation Capital’s values of agility, collaboration, entrepreneurial thinking, future-focus, impact, and inclusion,” said Kipton Currier, Vice President of Operations at Activation Capital. “The teams selected for the Innovation Center understand our commitment to the community, our excellence in execution focus, and our dedication to creating a nationally renowned life science innovation center for the benefit of future generations.”

Learn more here.

Recent News

08/14/2025

Virginia Catalyst announces Grant Round 18 awarded teams

August 13, 2025  – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.4 million in grants to three life and bioscience projects in the Commonwealth of Virginia through a highly-competitive Grant Round 18.   “The bioscience ecosystem in Virginia is vibrant, with university researchers,

08/13/2025

Governor Glenn Youngkin Launches University Commercialization Initiative to Fast-Track Startups and Accelerate Innovation

Governor Youngkin announces new Lab-to-Launch initiative to unlock innovation in Virginia by accelerating university research commercialization and technology transfer. Developed through a bold statewide collaboration between Virginia Innovation Partnership Corporation (VIPC) and Virginia’s six R1 research university partners – George Mason University, Old Dominion University, the University of Virginia, Virginia Commonwealth University, Virginia Tech, William

08/12/2025

CvilleBioHub Announces Expansion of the Commonwealth BioAccelerator Following $15M Investment from The Commonwealth of Virginia, UVA, and Regional Partners

CvilleBioHub will expand the Commonwealth BioAccelerator and state-of-the-art facilities at the North Fork Discovery Park. The expansion is powered by a transformational $15 million investment from the Commonwealth of Virginia and the University of Virginia. This funding establishes a commitment to life sciences entrepreneurship and commercialization in Virginia and signals a major leap forward for